This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Taltz
  • /
  • A Study of Ixekizumab (LY2439821) in Participants ...
Clinical trial

A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis (IXORA-S)

Read time: 2 mins
Last updated:30th Sep 2015
Identifier: NCT02561806

The main purpose of this study is to evaluate the efficacy of the study drug ixekizumab compared to ustekinumab in participants with moderate-to-severe-plaque psoriasis.

Study Type: Interventional  (Clinical Trial)
Actual Enrollment: 302 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A 52-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Ustekinumab in Patients With Moderate-to-Severe Plaque Psoriasis
Study Start Date: October 2015
Actual Primary Completion Date: May 2016
Actual Study Completion Date: October 2017

- Active Comparator:
- Experimental: Ixekizumab

Related journal:
- Ixekizumab provides superior efficacy compared with ustekinumab over 52-weeks of treatment: results from IXORA-S, a phase 3 study.

Category Value
Date last updated at source 2018-03-29
Study type(s) Interventional
Expected enrolment 302
Study start date 2015-10-01
Estimated primary completion date 2016-05-01

View full details